ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ...
Nasdaq

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
The American Journal of Managed Care

Papillary Muscle Scarring May Predict Cardiac Death in Dilated Cardiomyopathy

Papillary muscle scarring (papSCAR) is prevalent in one-third of DCM patients and predicts cardiac death independently. The FIDDLE technique significantly improves papSCAR detection sensitivity ...